HuR-Targeted Small-Molecule Inhibitors─Beneficial Impact in Cancer Therapy

2025/10/17 by Iwona Rzeszutek, Agnieszka Nowak-Król, Agnieszka Nowak‐Król · 1 citation
Biochemistry, Genetics and Molecular Biology · #RNA Research and Splicing #RNA modifications and cancer #RNA and protein synthesis mechanisms

paper · doi:10.1021/acs.jmedchem.5c01487

Abstract

Small-molecule inhibitors have become a major therapeutic class for cancer treatment. A growing body of evidence sheds light on HuR in cancer progression. HuR is an RNA-binding protein involved in all post-transcriptional regulation mechanisms dictating the transcript's fate in the cell. This prompted scientists to develop HuR-targeted small-molecule inhibitors (SMIs). Due to its advantages, targeted therapy using SMIs has entered an era where it accelerates the potential of cancer treatment. This account summarizes the role of HuR in cancer progression and the effect of known SMIs targeting HuR in numerous cancers, emphasizing the perspectives in this field.

Cited by

• RNA-Binding Proteins in Adipose Biology: From Mechanistic Understanding to Therapeutic Opportunities. [europepmc]

Related

• Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint
• Targeting the DNA damage response for cancer therapy
• Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
• Functional significance of the aryl hydrocarbon receptor in oncogenic signaling pathways
• Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells